Literature DB >> 27073722

CD24 negative lung cancer cells, possessing partial cancer stem cell properties, cannot be considered as cancer stem cells.

Haineng Xu1, Jiasheng Mu2, Jing Xiao3, Xiangsong Wu2, Maolan Li2, Tianrun Liu4, Xinyuan Liu3.   

Abstract

Cancer stem cells (CSCs) play vital role in lung cancer progression, resistance, metastasis and relapse. Identifying lung CSCs makers for lung CSCs targeting researches are critical for lung cancer therapy. In this study, utilizing previous identified lung CSCs as model, we compared the expression of CD24, CD133 and CD44 between CSCs and non-stem cancer cells. Increased ratio of CD24- cells were found in CSCs. CD24- cells were then sorted by flow cytometry and their proliferative ability, chemo-resistance property and in vivo tumor formation abilities were detected. A549 CD24- cells formed smaller colonies, slower proliferated in comparison to A549 CD24+ cells. Besides, A549 CD24- exhibited stronger resistance to chemotherapy drug. However, A549 CD24- didn't exert any stronger tumor formation ability in vivo, which is the gold standard of CSCs. These results showed that CD24- A549 cells showed some properties of CSCs but not actually CSCs. This study provides evidence that CD24 cannot be considered as lung CSCs marker.

Entities:  

Keywords:  A549; CD133; CD24; CD44; Lung cancer; biomarker; cancer stem cell marker; cancer stem cells

Year:  2015        PMID: 27073722      PMCID: PMC4759396     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  25 in total

1.  Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.

Authors:  Hong Jiang; Candelaria Gomez-Manzano; Hiroshi Aoki; Marta M Alonso; Seiji Kondo; Frank McCormick; Jing Xu; Yasuko Kondo; B Nebiyou Bekele; Howard Colman; Frederick F Lang; Juan Fueyo
Journal:  J Natl Cancer Inst       Date:  2007-09-11       Impact factor: 13.506

Review 2.  Notch inhibition as a promising new approach to cancer therapy.

Authors:  Benjamin Purow
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 3.  Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer.

Authors:  Christina S Baik; Marc C Chamberlain; Laura Q Chow
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

4.  Clinical significance of putative cancer stem cell marker CD44 in different histological subtypes of lung cancer.

Authors:  Raheleh Roudi; Zahra Madjd; Alireza Korourian; Mitra Mehrazma; Saadat Molanae; Mehrdad Nasrollahzadeh Sabet; Ahmad Shariftabrizi
Journal:  Cancer Biomark       Date:  2014       Impact factor: 4.388

5.  Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells.

Authors:  Eleftherios Sachlos; Ruth M Risueño; Sarah Laronde; Zoya Shapovalova; Jong-Hee Lee; Jennifer Russell; Monika Malig; Jamie D McNicol; Aline Fiebig-Comyn; Monica Graham; Marilyne Levadoux-Martin; Jung Bok Lee; Andrew O Giacomelli; John A Hassell; Daniela Fischer-Russell; Michael R Trus; Ronan Foley; Brian Leber; Anargyros Xenocostas; Eric D Brown; Tony J Collins; Mickie Bhatia
Journal:  Cell       Date:  2012-05-24       Impact factor: 41.582

6.  Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells.

Authors:  Maria M Ho; Alvin V Ng; Stephen Lam; Jaclyn Y Hung
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

7.  Tumor initiating potential of side population cells in human gastric cancer.

Authors:  Kazumasa Fukuda; Yoshiro Saikawa; Masaki Ohashi; Koshi Kumagai; Masaki Kitajima; Hideyuki Okano; Yumi Matsuzaki; Yuko Kitagawa
Journal:  Int J Oncol       Date:  2009-05       Impact factor: 5.650

8.  Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.

Authors:  Giulia Bertolini; Luca Roz; Paola Perego; Monica Tortoreto; Enrico Fontanella; Laura Gatti; Graziella Pratesi; Alessandra Fabbri; Francesca Andriani; Stella Tinelli; Elena Roz; Roberto Caserini; Salvatore Lo Vullo; Tiziana Camerini; Luigi Mariani; Domenico Delia; Elisa Calabrò; Ugo Pastorino; Gabriella Sozzi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

9.  Identification of gastric cancer stem cells using the cell surface marker CD44.

Authors:  Shigeo Takaishi; Tomoyuki Okumura; Shuiping Tu; Sophie S W Wang; Wataru Shibata; Ramanathan Vigneshwaran; Shanisha A K Gordon; Yutaka Shimada; Timothy C Wang
Journal:  Stem Cells       Date:  2009-05       Impact factor: 6.277

10.  Targeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus.

Authors:  Yu Yang; Haineng Xu; Weidan Huang; Miao Ding; Jing Xiao; Dongmei Yang; Huaguang Li; Xin-Yuan Liu; Liang Chu
Journal:  J Cell Mol Med       Date:  2015-02-16       Impact factor: 5.310

View more
  4 in total

1.  Sorting and biological characteristics analysis for side population cells in human primary hepatocellular carcinoma.

Authors:  Yegui Jiang; Hucheng Gao; Mingdong Liu; Qing Mao
Journal:  Am J Cancer Res       Date:  2016-09-01       Impact factor: 6.166

2.  NRP1-positive lung cancer cells possess tumor-initiating properties.

Authors:  Luis E Jimenez-Hernandez; Karla Vazquez-Santillan; Rosario Castro-Oropeza; Gustavo Martinez-Ruiz; Laura Muñoz-Galindo; Carolina Gonzalez-Torres; Carlo C Cortes-Gonzalez; Georgina Victoria-Acosta; Jorge Melendez-Zajgla; Vilma Maldonado
Journal:  Oncol Rep       Date:  2017-11-09       Impact factor: 3.906

3.  Identification of CD24 as a marker for tumorigenesis of melanoma.

Authors:  Ming-Rui Tang; Jia-Yan Guo; Di Wang; Nan Xu
Journal:  Onco Targets Ther       Date:  2018-06-12       Impact factor: 4.147

4.  Lactate-fueled oxidative metabolism drives DNA methyltransferase 1-mediated transcriptional co-activator with PDZ binding domain protein activation.

Authors:  Tao Huang; Xinglu Zhou; Xike Mao; Chenxi Yu; Zhijian Zhang; Jianke Yang; Yao Zhang; Tianyu Su; Chenchen Chen; Yuxiang Cao; Huijun Wei; Zhihao Wu
Journal:  Cancer Sci       Date:  2019-12-13       Impact factor: 6.716

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.